A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

The group B meningococcus adenovirus-based vaccine ChAdOx1 MenB.1 is safe and immunogenic in healthy volunteers.

Read the full article here

Related Articles